Some people with ANCA-associated vasculitis (AAV) have elevated biomarkers suggesting activation of the immune system’s complement cascade, which is…
Articles by Lindsey Shapiro, PhD
The selective immunosuppressive medication abatacept failed to significantly prevent treatment failure relative to a placebo in people with relapsing,…
Immune neutrophils and the weblike structures they release to trap and kill microbes — called neutrophil extracellular traps, or NETs…
The U.S. Food and Drug Administration (FDA) has approved Fasenra (benralizumab) for treating adults with eosinophilic granulomatosis with polyangiitis…
Fasenra (benralizumab), which is approved for a rare type of asthma, and Nucala (mepolizumab) were similarly effective at inducing…
End-stage kidney disease (ESKD) that required dialysis or a kidney transplant was associated with an elevated risk of death among…
A worse physical health-related quality of life (HRQoL) at diagnosis was associated with a higher mortality risk among a group…
A first patient has been dosed in a Phase 2 clinical trial testing lixudebart, Alentis Therapeutics‘ investigational antibody…
Blood levels of ANCAs — the disease-causing antibodies that give ANCA-associated vasculitis (AAV) its name — can be used…
ANCA-associated vasculitis (AAV) patients with kidney disease have significantly more activity among six genes associated with forming neutrophil extracellular…